Aprea Therapeutics Inc
Research Aprea Therapeutics Inc (APRE) on Bullrun: market cap USD 11.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPRE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.76M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 3.29M
- Free cash flow-USD 12.02M
Valuation Snapshot
latest market cap is USD 11.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 12.60M | -USD 12.89M | n/a | -1.93 | USD 14.60M | n/a | USD 12.44M |
| FY2024 | USD 0 | -USD 12.96M | -USD 13.57M | n/a | -2.35 | USD 22.85M | n/a | USD 19.31M |
| FY2023 | n/a | -USD 14.29M | -USD 12.27M | n/a | -3.95 | USD 21.61M | n/a | USD 16.95M |
| FY2022 | n/a | -USD 112.66M | n/a | n/a | -67.99 | USD 28.79M | USD 0 | USD 25.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 11.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.96M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.03M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 17.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 17.54M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 62.74M | n/a | n/a | n/a |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aprea Therapeutics Inc's market cap?
Aprea Therapeutics Inc's market capitalization is USD 11.76M.
What does Aprea Therapeutics Inc do?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.